<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Available Guidelines (as of March 21, 2020) in the treatment of COVID-19 for Chloroquine and Hydroxychloroquine.
   <xref rid="bib19" ref-type="bibr">
    <sup>19</sup>
   </xref>
   <sup>,</sup>
   <xref rid="bib21" ref-type="bibr">[21]</xref>, 
   <xref rid="bib22" ref-type="bibr">[22]</xref>, 
   <xref rid="bib23" ref-type="bibr">[23]</xref>, 
   <xref rid="bib24" ref-type="bibr">[24]</xref>, 
   <xref rid="bib25" ref-type="bibr">[25]</xref>, 
   <xref rid="bib26" ref-type="bibr">[26]</xref>, 
   <xref rid="bib27" ref-type="bibr">[27]</xref>, 
   <xref rid="bib28" ref-type="bibr">[28]</xref>
  </p>
 </caption>
 <alt-text id="alttext0015">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Study/Guidelines/Country</th>
    <th>Dose (adults)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Expert consensus from Department of Science and Technology and Health Commission of Guangdong province, China
     <xref rid="bib21" ref-type="bibr">
      <sup>21</sup>
     </xref>
    </td>
    <td align="left">Chloroquine phosphate 500 mg BID for 10 days.</td>
   </tr>
   <tr>
    <td align="left">Central Clinical Task Force, Korea
     <xref rid="bib22" ref-type="bibr">
      <sup>22</sup>
     </xref>
    </td>
    <td align="left">
     <underline>Moderate to severe COVID-19:</underline>
     <break/>Lopinavir 400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally per day or Hydroxychloroquine 400 mg orally per day for 7–10 days.
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Centre for Disease Control and Prevention, Atlanta, MICC Version 1 (March 12, 2020)
     <xref rid="bib23" ref-type="bibr">
      <sup>23</sup>
     </xref>
    </td>
    <td align="left">
     <underline>URTI plus positive PCR:</underline>
     <list list-type="simple" id="ulist0015">
      <list-item id="u0025">
       <label>•</label>
       <p id="p0130">Chloroquine phosphate 500 mg BID for 5 days.</p>
      </list-item>
      <list-item id="u0030">
       <label>•</label>
       <p id="p0135">Oseltamivir 150 mg BID for 5 days.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left">
     <underline>COVID-19 Pneumonia:</underline>
     <list list-type="simple" id="ulist0020">
      <list-item id="u0035">
       <label>•</label>
       <p id="p0140">Chloroquine phosphate 500 mg BID for 5 days plus Darunavir 800 mg/Cobicistat 150 mg OD for 2 weeks.</p>
      </list-item>
      <list-item id="u0040">
       <label>•</label>
       <p id="p0145">Atazanavir 400 mg OD for 2 weeks plus Oseltamivir 150 mg BID for 5 days.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left">The Dutch Center of Disease Control
     <xref rid="bib24" ref-type="bibr">
      <sup>24</sup>
     </xref>
    </td>
    <td align="left">600 mg of Chloroquine base followed by 300 mg after 12 h on day 1, then 300 mg × 2/day per person on days 2–5.</td>
   </tr>
   <tr>
    <td align="left">Italian Society of Infectious and Tropical Diseases (Lombardy Section)
     <xref rid="bib25" ref-type="bibr">
      <sup>25</sup>
     </xref>
    </td>
    <td align="left">
     <underline>Mild to moderate COVID-19</underline>:
     <break/>Lopinavir/ritonavir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10 days.
     <break/>
     <underline>Severe or critical COVID-19</underline>:
     <break/>Remdesivir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10–20 days.
    </td>
   </tr>
   <tr>
    <td align="left">Mount Sinai Health System, Canada
     <xref rid="bib26" ref-type="bibr">
      <sup>26</sup>
     </xref>
    </td>
    <td align="left">
     <underline>Moderate to severe COVID-19:</underline>
     <break/>Hydroxychloroquine 400 mg BID x 2 doses then 12 h later start 400 mg OD for 5–10 days.
    </td>
   </tr>
   <tr>
    <td align="left">Surviving Sepsis Campaign, The Society of Critical Care Medicine and the European Society of Intensive Care Medicine.
     <xref rid="bib27" ref-type="bibr">
      <sup>27</sup>
     </xref>
    </td>
    <td align="left">Insufficient evidence to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19 at this point of time.</td>
   </tr>
   <tr>
    <td align="left">Clinical guidance for patients with suspected or confirmed COVID-19 in Belgium
     <xref rid="bib28" ref-type="bibr">
      <sup>28</sup>
     </xref>
    </td>
    <td align="left">
     <underline>Mild/Moderate/Severe COVID-19</underline>:
     <break/>Hydroxychloroquine 400 mg at diagnosis, 400 mg 12 h later, followed by 200 mg BID for 5 days,
     <break/>Or,
     <break/>Chloroquine 600 mg at diagnosis and 300 mg 12 h later followed by 300 mg BID for 5 days (Consider lopinavir 400 mg/ritonavir 100 mg BID for 14 days as a second choice only if HCQ and chloroquine is contraindicated, provided it can be administered within 10 days after onset of symptoms)
     <break/>
     <underline>Critical COVID-19</underline>:
     <break/>Remdesivir 200 mg loading dose i.v within 30 min followed by 100 mg OD for 2–10 days (Hydroxychloroquine is second option if Remdesivir is unavailable)
    </td>
   </tr>
   <tr>
    <td align="left">Clinical guidance for patients with suspected or confirmed COVID-19 in Netherland
     <xref rid="bib28" ref-type="bibr">
      <sup>28</sup>
     </xref>
    </td>
    <td align="left">
     <underline>Mild/moderate/severe COVID-19</underline>:
     <break/>Chloroquine 600 mg on day 1, then 300 mg BID for 5 days (lopinavir/ritonavir as second option)
     <break/>
     <underline>Critical COVID-19</underline>:
     <break/>Remdesivir for 10 days plus chloroquine for 5 day
    </td>
   </tr>
   <tr>
    <td align="left">Gautret et al., Marseille, France
     <xref rid="bib19" ref-type="bibr">
      <sup>19</sup>
     </xref>
    </td>
    <td align="left">Hydroxychloroquine 200 mg TID for 10 days.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>OD-once daily, BID-twice daily, TID-thrice daily, URTI- upper respiratory tract infection, PCR-polymerase chain reaction, i.v - intravenous.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
